We examined the prognostic role of PD-11 and CD81 tumor infiltrating lymphocytes (TILs), and PD-L11 cells in patients with squamous cell carcinoma of the head and neck (SCCHN) treated with surgery and postoperative chemoradiotherapy (CRT). FFPE samples from 161 patients were immunohistochemically stained for PD-1, CD8 and PD-L1. The immune marker expression was correlated with clinicopathologic characteristics, and overall survival (OS), local progression-free survival (LPFS) and distant metastases free-survival (DMFS), also in the context of HPV16 DNA/p16 status. The median follow-up was 48 months (range: 4-100). The 2-year-OS was 84.1% for the entire cohort. High PD-1 and PD-L1 expression were more common in patients with positive HPV16 DNA (p < 0.001 and p 5 0.008, respectively) and high infiltration by CD81 TILs (p < 0.001 for both markers). High PD-L1 expression correlated with superior OS (p 5 0.025), LPFS (p 5 0.047) and DMFS (p 5 0.048) in multivariable analysis, whereas no significance could be demonstrated for PD-1. Patients with CD8 high /PD-L1 high expression had favorable outcome (p < 0.001 for all endpoints) compared to other groups. We validated the superior OS data on CD8 high /PD-L1 high using the Cancer Genome Atlas TCGA dataset (n 5 518; p 5 0.032). High PD-L1 expression was a favorable prognostic
marker in HPV16-negative but not HPV16-positive patients. In conclusion, HPV-positive tumors showed higher expression of immune markers. PD-L1 expression constitutes an independent prognostic marker in SCCHN patients post-adjuvant CRT. In conjunction with CD8 status, these data provide an important insight on the immune contexture of SCCHN and are directly relevant for future treatment stratification with PD-1/PD-L1 immune checkpoint inhibitors to complement CRT.
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most common malignancy worldwide. 1 Historically, tobacco and alcohol use constituted the main risk factors for SCCHN. However, human papillomavirus (HPV) infection, mainly genotype 16, is encountered in approximately 25% of SCCHN and represents the main etiology in a progressively expanding subset of patients with SCCHN, especially oropharyngeal cancer. [2] [3] [4] HPV-positivity has been associated with improved response and superior survival rates after radiotherapy and chemoradiotherapy (CRT) compared to patients with HPV-negative tumors. 5, 6 HPV-positive tumor cells express E6 and E7 viral proteins that can trigger an immune response. 7 Also, a strong infiltration by CD81 tumor infiltrating lymphocytes (TILs) has been reported to be associated with a favorable clinical course in several human malignancies. 8 Accordingly, we have recently shown that CD81 TILs infiltration was correlated with human papilloma virus 16 (HPV16) status and improved clinical outcome in patients with SCCHN treated CRT in the primary and adjuvant setting. 9 However, the immune contexture mediating response of HPV-positive SCCHN after CRT have not yet been completely elucidated.
Programmed cell death protein-1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1) mediate immune tolerance and promote the formation of an immunoprivileged site for tumor progression. 10, 11 PD-L1 is expressed on cancer cells, parenchymal and myeloid cells, whereas PD-1 is found on TILs. Activation of PD-1/PD-L1 impairs TILs function 10, 11 and occurs commonly in tumors via either oncogenic signaling (innate immune resistance), or an inflammatory process mediated by interferon-g (adaptive immune resistance). [10] [11] [12] Monoclonal antibodies against PD-1/PD-L1 have demonstrated impressive response rates in melanoma, lung, and renal-cell carcinoma. 11 Recent trials confirmed the efficacy of PD-1 targeting using nivolumab and pembrolizumab in metastasized/recurrent SCCHN. [13] [14] [15] Hence, there is an emerging interest for implementing these drugs as first line treatment, for example, in combination with CRT. In addition, exploring potential prognostic biomarkers for immunotherapy will be important to facilitate their successful implementation in the non-metastatic clinical setting.
In this retrospective analysis, we examined the prognostic role of PD-1/PD-L1 axis alone, and also in the context of HPV16 DNA/p16 in a large, multicenter cohort of patients with locally advanced SCCHN homogeneously treated with surgery and postoperative CRT.
Patients and Methods

Patient and treatment characteristics
Patients were treated with surgery and postoperative cisplatin-based CRT for SCCHN between 2004 and 2012. Written consent from all patients had been obtained. The eligibility criteria and treatment protocol have been reported before 16 and included: histologically confirmed invasive cancer of either the oro, hypopharynx or oral cavity, and patients that received radical surgery including neck dissection. Postoperative CRT was performed in cases of extracapsular spread and/or positive resection margins and/or pT4-stage and 4 positive lymph nodes. Uninvolved cervical nodes received an elective treatment with a median dose of 50.4 Gy and a boost to the former tumor region and/or residual disease up to 60-66 Gy was implemented. Thermoplastic masks were used for immobilization and the radiotherapy was administered using linear accelerators with energies 6 MeV with either 3D-conventional or IMRTplanning. The median cumulative cisplatin dose was 200 mg/ m 2 . Contrast-enhanced CT-, MRI-or PET-CT-scans were used for treatment planning and for follow up. In total, n 5 221 patients that fulfilled all criteria were included in the study. Formalin-fixed, paraffin-embedded (FFPE) specimens originating from the tumor-resections were acquired. This What's new? Human papillomavirus (HPV)-positivity in squamous cell carcinoma of the head and neck (SCCHN) has been associated with improved response and superior survival rates after radiotherapy and chemoradiotherapy (CRT) compared to patients with HPV-negative tumors. However, the impact of immune checkpoint contexture in SCCHN treated with adjuvant CRT remains unclear. Here, the authors show that PD-L1 constitutes an independent prognostic marker. The immune phenotype I (CD8high/PD-L1high) is more common in HPV16-positive tumors and associated with favorable patient outcome. The findings provide a rationale for examining the therapeutic potential of using PD-1/PD-L1 immune checkpoint inhibitors in combination with CRT in SCCHN.
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tissue was centrally collected, as well as clinical data, radiotherapy plans and diagnostic images using the DKTK RadPlanBio Platform at the DKTK partner site Dresden. From the 221 cases, sufficient material for analysis of lymphocyte and marker expression in all three tumor compartments (intratumoral, stromal and invasive front) was available in 161 cases. This trial was approved by the ethical committees of all eight DKTK partner sites.
Immunohistochemical staining and scoring of immune markers
Slides from 161 patients were subjected to an automatic staining procedure using a standardized DAKO EnVision TM FLEX Peroxidase Blocking reagent (K8000, DAKO, Hamburg, Germany) and a DAKO Autostainer Link 48 (DAKO). Antigen retrieval was facilitated by pretreatment of the paraffin sections (SuperFrost Plus, Thermo Scientific) with either an Epitope Retrieval Solution (Trilog, Cell Marque, Rocklin, CA) or Citrate Buffer 6.0 (Abcam) for 20 min. Slides were stained with the primary antibodies for either CD8 (1:100, clone C8/ 144B; Dako M7103), PD-1 (1:100, clone NAT105; Abcam AB52587) and PD-L1 (1:50, clone E1L3N(R); Cell Signal Technology) for 120 min at room temperature. Subsequently, dextran polymer conjugated horseradish peroxidase and 3,3 0 -diamino-benzidine (DAB) chromogen or LSAB Detection system (PD-1, K5005, Dako) was used to visualize the epitope-antibody reaction product. Counterstaining was conducted using hematoxylin solution (Gill 3, Sigma Aldrich, Munich, Germany). Negative control slides in the absence of primary antibodies were included.
The expression of PD-11 and CD81 tumor infiltrating lymphocytes (TILs) was scored semi-quantitatively via measurement of cell density as described before. 16, 17 Scoring was as follows: (i) no, or sporadic cells; (ii) moderate numbers of cells; (iii) abundant occurrence of cells and (iv) highly abundant occurrence of cells. Cells positive for PD-1 were also assessed in the intratumoral compartment, in the invasive front and in the stromal compartment separately. The total score was calculated by adding the separate scores from all three compartments (range, 3 to 12). The median score was used as cut-off to classify patients into two groups: low or high PD-1 and PD-L1 expression. PD-L11 tumor (and myeloid cells) were evaluated for each sample in different representative fields and due to lack of a standardized scoring system all cases with expression in 5% of the cells were considered positive. 13, 18 We did not score PD-L1 separately in the intra-epithelial and stromal compartment.
PCR-based HPV16-status evaluation and histochemical p16
INK4a expression were performed centrally as reported before. 19 Images were acquired with the AxioImager Z1 microscope using the Axiovision 4.6 software (Zeiss, Germany). To minimize interobserver variability, two investigators (PB, FR) without knowledge of the clinicopathologic data performed scoring. In cases of discrepancy, a final decision was made after additional examination of the specimens.
Head and neck cancer genome atlas datasets
Data for SCCHN available from The Cancer Genome Atlas (TCGA) were accessed in January 2017. In the original report of TCGA, several methods were used to assess HPV status including p16 staining, in-situ hybridization, RNA sequencing, whole exome and whole genome sequencing. 20 In this work, we used the HNSCC TCGA dataset (n 5 518 samples), and additionally stratified this dataset to include only samples with known HPV status based on p16 staining (p16-positive: n 5 38 patients; p16-negative: n 5 71 patients; total: n 5 109 patients). The dataset was obtained from the TCGA Data Portal (https://tcga-data.nci.nih.gov).
Statistical analysis
The Spearman test assessed the correlation between the different parameters. Overall survival (OS) was calculated from the beginning of CRT to the time of death from any cause, or the last follow-up. Local progression-free survival (LPFS) was measured from the beginning of CRT to the day of locoregional failure or death from any cause. Distant metastases-free survival (DMFS) was calculated from the beginning of CRT to detection of metastasis or death for any reasons. Data from patients who were alive and free of recurrences were censored for these endpoints. Univariate and multivariable analyses were conducted using the log-rank test and the Cox proportional hazard model (backwards selection method), respectively. The Kaplan-Meier method was used to plot the clinical endpoints. Due to multicolinearity between HPV16 DNA and p16, multivariable analyses were conducted only including HPV16 DNA. Only parameters found to be significant in the univariable analysis were included in the multivariable one. Extracapsular spread (ECE), was only "borderline significant" for OS, but significant for LPFS and DMFS and so was also included in the first analysis. A p < 0.05 was considered statistically significant. Statistical analyses were performed using the IBP SPSS21 software.
Results
Immune marker expression and correlation with clinical parameters
As a dichotomous variable, PD-1 expression was defined as being "low" (weighted score <4) in 88 patients (54.7%) and "high" (weighted score 4) in 73 patients (45.3%), according to the median score. PD-L1 expression was defined as "low" (<5%) in 98 patients (60.9%) and "high" (5%) in 63 patients (39.1%). CD81 TILs score has been reported before. 16 Representative images of tumors with high PD-1
and PD-L1 expression are shown in Figure 1 . Regarding HPV, there were 61 (37.9%) and 100 (62.1%) patients with HPV16-positive and HPV16-negative tumors, respectively. Also, there were 67 (41.6%) and 94 (58.4%) patients with p16-positive and p16-negative tumors, respectively.
Tumors with a high PD-1 and PD-L1 expression were more common in patients with oropharyngeal tumor localization (p < 0.001 and p 5 0.034, respectively), positive HPV16 DNA status (p < 0.001 and p 5 0.008, respectively), p16-positivity (p 5 0.007 and p 5 0.002, respectively), and higher intratumoral infiltration by CD81 cells (p < 0.001 for both markers; Table 1 ). We also examined the expression of HPV16 DNA, p16, PD-1 and PD-L1 in the different anatomical subgroups (oral cavity, oropharynx, hypopharynx,) as shown in Supplementary Table 1. The incidence of high expression was significantly higher in oropharynx compared to the other two anatomical localizations for all immune markers (Supporting Information Table 1 ). We failed to identify any further significant relationship between PD-1/PD-L1 and clinicopathological parameters (Table 1) .
Clinical outcome and prognostic value of PD-L1/PD-1
The median follow-up amounted to 48 (range, 4-100) months. The 2-year-OS was 84.5% for the entire patient cohort. Patients with high PD-L1 expression had a significantly superior OS (low vs. high PD-L1: mean 61.6 vs. 84.6 months; p 5 0.005), LPFS (low vs. high PD-L1: mean 56.3 vs. 80.1 months; p 5 0.005) and DMFS (low vs. high PD-L1: mean 56.9 vs. 81.6 months; p 5 0.003) in univariate analysis ( Fig. 2 and Table 2 ). In contrast, PD-1 expression lacked prognostic significance for either clinical endpoint. As shown before, 16 early T-stage, and positive HPV16 and p16 status predicted for significantly superior outcome for all endpoints, whereas ECE was associated with worse DMFS (p 5 0.026; Table 2 ).
Notwithstanding the limitation of the small patient number, we have also analyzed the prognostic role of HPV16 DNA, p16, PD-1 and PD-L1 in the different anatomical subgroups (oral cavity, oropharynx, hypopharynx). We found that high expression of HPV16 DNA, p16 and PD-L1 correlated with superior outcome in oropharynx but not in patients with other anatomical localizations (Supporting Information Table 2 ).
We performed a multivariable analysis by including factors that were significant in univariate analysis (Table 2 ). In the Cox model, high PD-L1 expression was confirmed as an independent prognostic parameter for OS (p 5 (Table 2) .
Because total expression of PD-11 TILs lacked prognostic significance, we examined its impact in the different tumor compartments (intratumoral, stromal and invasive margin) separately. High PD-1 expression in the intratumoral compartment showed a significantly positive correlation with OS (p 5 0.015), LPFS (p 5 0.013) and DMFS (p 5 0.008) (Supporting Information Fig. 1 ; Supporting Information Table 3) . Similarly, strong PD-1 expression at the invasive margin predicted for superior OS (p 5 0.017) and DMFS (p 5 0.018), whereas stromal expression lacked prognostic significance (Supporting Information Fig. 2 ; Supporting Information Table 3 ).
Impact of combined CD8/PD-L1 expression in the DKTK-ROG and TCGA cohorts Recent studies have proposed combining the expression of CD81 TILs and PD-L11 cells to assess tumor immunophenotype and guide immunotherapies. 21 Fig. 3a) . We aimed to cross-validate our findings on the prognostic role of the combined CD8/PD-L1 status by using the SCCHN TCGA dataset 20 that included patients with known and unknown HPV status (n 5 518; Fig. 3b ). In line with our data, analysis of the entire SCCHN TCGA dataset revealed superior OS for patients with CD8 high /PD-L1 high expression and CD8 high /PD-L1 l 8 w groups compared to the other groups (p 5 0.032). Furthermore, we examined the distribution of the four groups in the context of HPV status in our DKTK-ROG cohort and the TCGA dataset with known HPV p16 status (n 5 109) (Fig. 3c) 
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Prognostic impact of PD-1/PD-L1 in the context of HPV16 status
Because HPV is directly linked to tumor immunogenicity, we also analyzed the prognostic impact of PD-L1 in the context of HPV16-DNA-status. Patients with positive HPV16 DNA status presented a superior outcome compared to patients with negative HPV16 DNA in univariate analysis (OS: p < 0.001; LPFS p < 0.001 and DMFS: p < 0.001; Supporting Information Table 2 ). In patients with HPV16 DNA-negative tumors, high PD-L1 expression was a strong prognostic parameter for OS (p 5 0.045), LPFS (p 5 0.044) and DMFS (p 5 0.037; Fig. 4a ; Supporting Information Table 4 ). In contrast, the PD-L1 status did not affect the clinical outcome in HPV16-positive patients. In line to the findings in the entire cohort, we failed to detect a prognostic significance for PD-1 in the context of HPV16 DNA status. Finally, we examined the role of combined HPV16/PD-L1 expression. Comparison of the outcome between the four different subgroups revealed a better prognosis in patients with HPV16 (1) /PD-L1 high and HPV16 
Discussion
Several studies have shown that patients with HPV16 SCCHN have more favorable prognosis after CRT compared to HPV16-negative patients. 5, 23 Although various mechanisms such as upregulation of p53, altered apoptosis and impaired repair of DNA damage have been proposed to explain the better outcome after CRT, 24 accumulating evidence suggests that the enhanced immunogenicity observed in HPV-positive tumors might contribute to the improved survival. Recent work has assessed the role of PD-1/PD-L1 axis in patients with SCCHN but its prognostic value in the context of HPV remains largely unexplored. Here, we found that patients with HPV16-positive tumors had significantly higher infiltration by CD81 and PD-11 TILs, and PD-L1-positive cells. These data built on previous reports that infection with HPV can render tumors more immunogenic. 7, 25 Importantly, patients with strong total PD-L1 expression had a significantly lower incidence of local and distant recurrence compared to patients with low PD-L1 expression that remained independent of other clinicopathologic factors.
The importance of CD81 TILs in mediating response to RT/CRT and their positive prognostic impact in human malignancies has been well characterized. 26, 27 Total PD-11
TILs expression failed to predict for the clinical course in our series. Mixed findings have been reported regarding the role of PD-11 TILs that varied depending on tumor type. Indeed, a favorable role has been revealed for PD-11 TILs in ovarian, pancreatic, colorectal cancers, [28] [29] [30] [31] [32] [33] whereas in prostate, renal and lung cancers, and melanoma high PD-1 expression was associated with worse survival rates. [34] [35] [36] Of note, the prognostic role of this immune marker was tumor compartment-dependent in our work. High PD-11 TILs expression in the intratumoral compartment and invasive margin but not stromal compartment predicted for better local and distant control. Mixed data have been found on the clinical impact of TILs according to the tumor compartment, possibly due to heterogeneous treatment and patient cohorts. 9, 17, [37] [38] [39] Even though the correlation of PD-L1 and compartmentdependent PD-11 TILs expression with better outcome was unexpected as these markers are directly linked to immunosuppression, various mechanisms could explain this paradox. Antigen-specific immune activation upon T-cell receptor stimulation can upregulate PD-1 on TILs. 40 In SCCHN, enhanced expression of the immune activation markers HLA-DR and CD38 in PD-11 TILs has been observed as compared with PD-1-TILs. 30 In that work, TILs were functional after blockade of the PD-1/PD-L1 axis, and high PD-1 expression was positively correlated with a favorable clinical outcome that is in line to our tumor compartment data. Therefore, PD-11 TILs and constitutive PD-L1 expression could represent a previous endogenous antitumor immune response that decelerated but failed to completely halt tumor growth, and could be reinvigorated using PD-1/PD-L1 inhibitors.
Tumor Immunology and Microenvironment
11
Only few studies have assessed the prognostic value of PD-L1 in SCCHN. Straub et al. reported an adverse role for PD-L1 in 80 patients, 41 whereas Kim et al. failed to detect a prognostic impact in 133 patients. 42 However, treatment in both studies was heterogeneous including primary surgery alone, or with adjuvant radiotherapy/CRT, or even CRT alone, whereas prognosis in the context of HPV was not examined that make data interpretation difficult. Lin et al. demonstrated an adverse impact for PD-L1 overexpression in 305 patients but this study lacked information on HPV and adjuvant treatment even though 30% of patients had advanced disease. 43 Kim et al. observed a favorable prognostic role for high immune cell PD-L1 expression in 402 patients. 44 Again, adjuvant treatment was heterogeneous including CRT in only 25%, RT alone in 37.8% and no treatment in 36.5% of patients. 44 In contrast, our cohort included patients treated homogeneously with adjuvant CRT per well-defined criteria.
Previous investigations have recommended studying PD-L1 in the context of CD81 TILs to better characterize the tumor immune phenotype. 21 21, 22 A recent report based on the entire TCGA atlas (32 tumor types; n 5 9677 cases) found a strong correlation between type I tumors and HPV-positivity. 25 In line to this, we found that patients with type I (CD8 high /PD-L1 high ) SCCHN were significantly more common in HPV-positive compared to HPV-negative tumors both in our DKTK-ROG cohort and the SCCHN TCGA dataset. Additionally, in our series, type I (CD8 high /PD-L1 high ) and type IV SCCHN (CD8 high /PD-L1 l 8 w ) presented favorable OS compared to the other groups, which we also validated using the TCGA dataset. These findings are of direct clinical relevance as melanoma patients that responded to PD-1/PD-L1 blockade had strong baseline expression of CD81 and PD-11 TILs, and PD-L1 upregulation. 11, 30 Such adaptive immune resistance has also been found in Merkel cell carcinoma 46 and breast cancer. 47 Thus, our observations provide important insight for the combination of immunotherapeutics Tumor Immunology and Microenvironment with CRT in SCCHN since type I malignancies are most likely to benefit from PD-1/PD-L1 blockade. Such a treatment concept is also attractive as CRT can activate TILs following immunogenic cancer cell death. 48 In recurrent/metastatic head and neck cancer, patients with high PD-L1 expression also showed better response and superior survival after treatment with the immune checkpoint inhibitors nivolumab and pembrolizumab. The effect in the non-recurrent/metastatic setting is currently being explored in several trials. [13] [14] [15] Our work has limitations. First, the retrospective design of this analysis cannot exclude potential selection bias. Second, scoring of PD-1/PD-L1 was performed using a nonautomated system. Third, the median follow-up was relatively short. Undoubtedly, these findings should be validated in prospective clinical cohorts, such as the currently ongoing prospective study (HNpr€ adBio) of the DKTK-ROG.
In summary, we here showed that HPV16 positivity strongly correlated with CD81 and PD-11 TILs, and PD-L1 in patients with SCCHN treated with adjuvant CRT. In conjunction with CD8, PD-L1 represents a promising prognostic marker and could be used to guide treatment with PD-1/PD-L1 inhibitors. Relevant to the latter, recent clinical trials in patients with recurrent or metastatic SCCHN demonstrated promising results using the PD-1 inhibitors nivolumab and pembrolizumab. [13] [14] [15] Our findings provide a rationale for examining the therapeutic potential of PD-1/PD-L1 immune checkpoint inhibitors with CRT to improve the outcome in SCCHN. 
